Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher

Henry Schein remains a dominant global provider of dental and medical practitioner supplies, with recent share price outperformance versus the S&P 500. HSIC delivered strong Q2 results: revenue up 6.7% to $3.46B, net income and cash flow both meaningfully improved, and all business segments showed growth. Management raised 2026 guidance, now expecting 4.5–5.5% revenue growth and adjusted EPS of $5.29–$5.39, reflecting ongoing operational momentum.

Seeking Alpha • Sep 19, 2026

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Sep 18, 2026

Here's Why Henry Schein (HSIC) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Sep 16, 2026

What Makes Henry Schein (HSIC) a New Buy Stock

Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Sep 16, 2026

Henry Schein: Growth Is Improving, But The Valuation Stays Cheap

Henry Schein is rated buy with a 12-month price target of $104, reflecting accelerating organic growth, margin expansion, and substantial share repurchases. Q2 2026 results showed 4.6% internal growth, 48 bps gross margin expansion, and a 6.7% reduction in diluted share count, signaling improved business quality. The BOLD+1 cost program targets $125M+ in annual run-rate operating income gains by end-2026, supporting double-digit earnings growth potential into 2027.

Seeking Alpha • Sep 16, 2026

HSIC or SAUHY: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Dental Supplies stocks are likely familiar with Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Sep 16, 2026

Henry Schein, Inc. (HSIC) Presents at 2026 Global Healthcare Conference Transcript

Henry Schein, Inc. (HSIC) Presents at 2026 Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Applied BioCode Announces Distribution Agreement with Henry Schein

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)-- #ClinicalDiagnostics--Applied BioCode today announced a distribution agreement with Henry Schein, a leading provider of healthcare products and services, to expand the availability of its BioCode® MDx-3000 System and comprehensive molecular diagnostics menu. The BioCode® MDx-3000 is an automated, high-throughput multiplex molecular diagnostic platform designed to support high-complexity clinical laboratories. Its testing menu includes upper respiratory and gastrointestinal.

Business Wire • Sep 8, 2026

Henry Schein to Participate in Upcoming Investor Conference in September

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will present at the following conference in September: Baird Global Healthcare Conference at the InterContinental Hotel, New York City on September 15, 2026, at 12:15 p.m. EDT. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on t.

Business Wire • Sep 8, 2026

Why Is Henry Schein (HSIC) Up 0.9% Since Last Earnings Report?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026